158 related articles for article (PubMed ID: 8483079)
1. Imaging of neuroblastoma in patients identified by mass screening using urinary catecholamine metabolites.
Tanabe M; Yoshida H; Ohnuma N; Iwai J; Takahashi H
J Pediatr Surg; 1993 Apr; 28(4):617-21. PubMed ID: 8483079
[TBL] [Abstract][Full Text] [Related]
2. Mass screening for neuroblastoma in Miyagi Prefecture.
Itano M; Morita S; Fujie H; Ohashi Y; Minegishi N; Minegishi M; Yamaguchi Y; Sato T; Tsuchiya S; Konno T
Tohoku J Exp Med; 1992 Oct; 168(2):137-9. PubMed ID: 1306297
[TBL] [Abstract][Full Text] [Related]
3. Natural course of neuroblastoma detected by mass screening: s 5-year prospective study at a single institution.
Nishihira H; Toyoda Y; Tanaka Y; Ijiri R; Aida N; Takeuchi M; Ohnuma K; Kigasawa H; Kato K; Nishi T
J Clin Oncol; 2000 Aug; 18(16):3012-7. PubMed ID: 10944135
[TBL] [Abstract][Full Text] [Related]
4. Outcome of infants with neuroblastoma detected by mass screening and surgically treated in Shiga Prefecture, Japan: what is the role of surgery?
Hase T; Ohta S; Tani T; Mizukuro T; Mekata E; Naitoh H; Shimadera S; Fujino S; Taga T
Pediatr Surg Int; 2002 Sep; 18(5-6):289-94. PubMed ID: 12415341
[TBL] [Abstract][Full Text] [Related]
5. Simple liquid-chromatographic measurement of vanillylmandelic acid and homovanillic acid in urine on filter paper for mass screening of neuroblastoma in infants.
Hanai J; Kawai T; Sato Y; Takasugi N; Nishi M; Takeda T
Clin Chem; 1987 Nov; 33(11):2043-6. PubMed ID: 3677377
[TBL] [Abstract][Full Text] [Related]
6. Imaging evaluation of infants with neuroblastoma detected by VMA screening spot test.
Fujioka M; Saiki N; Aihara T; Yamamoto K
Pediatr Radiol; 1988; 18(6):479-83. PubMed ID: 3054769
[TBL] [Abstract][Full Text] [Related]
7. Fluctuation in the concentrations of vanillylmandelic acid and homovanillic acid in mass screening for neuroblastoma.
Nishi M; Miyake H; Takeda T; Yamashiro K; Takasugi N; Hanai J; Kawai T
Eur J Pediatr; 1990 Sep; 149(12):859-61. PubMed ID: 2226572
[TBL] [Abstract][Full Text] [Related]
8. Mass screening for neuroblastoma in infants in Japan. Interim report of a mass screening study group.
Sawada T; Hirayama M; Nakata T; Takeda T; Takasugi N; Mori T; Maeda K; Koide R; Hanawa Y; Tsunoda A
Lancet; 1984 Aug; 2(8397):271-3. PubMed ID: 6146820
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of magnetic resonance imaging in treatment of neuroblastoma].
Ohnuma N; Takahashi H; Tanabe M; Yoshida H; Iwai J; Higashimoto Y; Shimbo K
Nihon Geka Gakkai Zasshi; 1992 Jun; 93(6):646-50. PubMed ID: 1630440
[TBL] [Abstract][Full Text] [Related]
10. Role of ultrasound in managing neuroblastoma detected by mass screening: a proposed ultrasonographic grading for children with neuroblastoma.
Hirata T; Tatara H; Zaizen Y; Suita S; Matsuzaki A; Ueda K
J Clin Ultrasound; 1995 Jun; 23(5):305-13. PubMed ID: 7642769
[TBL] [Abstract][Full Text] [Related]
11. Method of measurement of urinary homovanillic acid and vanillylmandelic acid by gas chromatography-mass spectrometry suitable for neuroblastoma screening.
Seviour JA; McGill AC; Dale G; Craft AW
J Chromatogr; 1988 Nov; 432():273-7. PubMed ID: 3220894
[No Abstract] [Full Text] [Related]
12. Results for 79 patients with neuroblastoma detected through mass screening at 6 months of age in a single institute.
Nishio N; Mimaya J; Nara T; Takashima Y; Horikoshi Y; Urushihara N; Hasegawa S; Aoki K; Hamasaki M
Pediatr Int; 2006 Dec; 48(6):531-5. PubMed ID: 17168969
[TBL] [Abstract][Full Text] [Related]
13. Different genomic and metabolic patterns between mass screening-positive and mass screening-negative later-presenting neuroblastomas.
Nakagawara A; Zaizen Y; Ikeda K; Suita S; Ohgami H; Nagahara N; Sera Y; Akiyama H; Kawakami K; Uchino J
Cancer; 1991 Nov; 68(9):2037-44. PubMed ID: 1913552
[TBL] [Abstract][Full Text] [Related]
14. Studies on tyrosine hydroxylase in neuroblastoma in relation to urinary levels of catecholamine metabolites.
Imashuku S; Takada H; Sawada T; Nakamura T; LaBrosse EH
Cancer; 1975 Aug; 36(2):450-7. PubMed ID: 239788
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up results of the observation program for neuroblastoma detected at 6-month mass screening.
Arakawa A; Oguma E; Aihara T; Kishimoto H; Kikuchi A; Hanada R; Koh K
J Pediatr; 2014 Oct; 165(4):855-7.e1. PubMed ID: 25091258
[TBL] [Abstract][Full Text] [Related]
16. Stephen L. Gans overseas lecture. Mass screening for neuroblastoma in Japan: lessons learned and future directions.
Suita S
J Pediatr Surg; 2002 Jul; 37(7):949-54. PubMed ID: 12077747
[TBL] [Abstract][Full Text] [Related]
17. Mass screening for neuroblastoma in infants.
Wei M; Ye M; Dong K; Dong R
Discov Med; 2020; 30(160):63-70. PubMed ID: 33382962
[TBL] [Abstract][Full Text] [Related]
18. Screening for neuroblastoma and age-specific incidence.
Moe PJ
Acta Paediatr; 1999 Apr; 88(4):362-4. PubMed ID: 10342530
[No Abstract] [Full Text] [Related]
19. Screening for neuroblastoma in North America. 2-year results from the Quebec Project.
Woods WG; Tuchman M; Bernstein ML; Leclerc JM; Brisson L; Look T; Brodeur GM; Shimada H; Hann HL; Robison LL
Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):312-9. PubMed ID: 1456396
[TBL] [Abstract][Full Text] [Related]
20. Problems of neuroblastoma screening for 6 month olds and results of second screening for 18 month olds.
Hayashi Y; Ohi R; Yaoita S; Nakamura M; Kikuchi Y; Konno T; Tsuchiya S; Shiraishi H
J Pediatr Surg; 1995 Mar; 30(3):467-70. PubMed ID: 7760244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
